Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday: Data From a Single Outpatient Endocrine Clinic.
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Meir Medical Center
- Enrollment
- 150
- Locations
- 1
- Primary Endpoint
- Compliance and persistence to osteoporosis drug therapy
Study Overview
Brief Summary
The purpose of the study is to provide information about the rate of response and persistence to drug therapies for osteoporosis. Another issue examined in this study refers to the preferences and concerns about future treatments in patients during "drug holiday".
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 40 Years to 90 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Postmenopausal women
- •Diagnosis of osteoporosis in the medical record
- •At least one prescription drug to treat osteoporosis in the last 5 years
- •Insured by "Clalit" Health Services
- •Hebrew-speaking capability and readiness to answer a questionnaire
Exclusion Criteria
- •Premenopausal women
- •No diagnosis of osteoporosis in the medical record
- •No treatment for osteoporosis in the last 5 years
- •Women who do not speak Hebrew or are unable to answer a questionnaire
Outcomes
Primary Outcomes
Compliance and persistence to osteoporosis drug therapy
Time Frame: Participants will be followed for the duration of their clinic visit, an average of 5 hours
Data collection will be done by questionnaires and from the medical record of the patient. The information collected will include: demographic information, measurements of bone density, additional information about the disease and treatment that the patient receives,prescription purchases and additional drugs the patient is taking (steroids, PPI's(Proton Pump Inhibitors) / H2 receptor antagonists and NSAIDs(Non Steroidal Anti Inflammatories)).
Secondary Outcomes
No secondary outcomes reported